HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?

Abstract
The aim of this study is to examine the relationship between the expression level of excision repair cross-complementation group 1 (ERCC1) and of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) in various thoracic neoplasm.Three hundreds-eight patients [non-small cell lung cancer (NSCLC)(n=56), malignant pleural mesothelioma (MPM)(n=21), pulmonary metastatic tumors (PMT)(n=148), thymic epithelial tumors (n=49) and pulmonary neuroendocrine tumor (n=34)] who underwent 18F-FDG PET before treatment were included in this study. Tumors sections were stained by immunohistochemistry for ERCC1, glucose transporter 1(Glut1), vascular endothelial growth factor (VEGF) and microvessel density (MVD) by determinate by CD34. The expression of ERCC1 in thoracic neoplasms had a positivity of 49% (152/308), and the positive rates of ERCC1 expression in NSCLC, PMT, thymic epithelial tumor, pulmonary neuroendocrine tumor and MPM were 52, 43, 53, 47 and 85%, respectively. The positivity of ERCC1 expression was significantly higher in MPM and SQC than in the other histological types. A statistically significant correlation between ERCC1 expression and 18F-FDG uptake was observed in thymic epithelial tumors, especially thymoma. Moreover, ERCC1 expression was also closely associated with the expression of Glut1, VEGF and MVD.Our results indicated that 18F-FDG uptake may be an alternative biomarker for predicting ERCC1 expression in patients with thymoma.
AuthorsK Kaira, M Endo, T Shukuya, H Kenmotsu, T Naito, A Ono, A Tsuya, Y Nakamua, T Takahashi, H Murakami, H Kondo, T Nakajima, N Yamamoto
JournalNeoplasma (Neoplasma) Vol. 59 Issue 3 Pg. 257-63 ( 2012) ISSN: 0028-2685 [Print] Slovakia
PMID22329847 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD34
  • DNA-Binding Proteins
  • Glucose Transporter Type 1
  • Radiopharmaceuticals
  • SLC2A1 protein, human
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Fluorodeoxyglucose F18
  • ERCC1 protein, human
  • Endonucleases
Topics
  • Aged
  • Antigens, CD34 (metabolism)
  • DNA-Binding Proteins (metabolism)
  • Endonucleases (metabolism)
  • Female
  • Fluorodeoxyglucose F18
  • Glucose Transporter Type 1 (metabolism)
  • Humans
  • Immunoenzyme Techniques
  • Male
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Thoracic Neoplasms (diagnostic imaging, metabolism, pathology)
  • Thymus Neoplasms (diagnostic imaging, metabolism, pathology)
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: